GRAIL Appoints Sarah Krevans to Board of Directors

GRALV 10.21.2024

Full Press ReleaseSEC FilingsOur GRALV Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
  • 12.18.2024 - GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

    MENLO PARK, Calif.,Oct. 21, 2024/PRNewswire/ --GRAIL, Inc.(Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment ofSarah Krevansto its Board of Directors, effective immediately.Ms. Krevanswill also serve as a member of the Board's Audit Committee, Compensation Committee, andNominating and Governance Committee. Following the appointment ofMs. Krevans, the Board will be composed of five directors, four of whom are independent.

    CEO Sutter Health

    Ms. Krevansserved as president and CEO ofSutter Health, aNorthern Californiabased not-for-profit health system in one of the most diverse and innovative regions in the nation, from 2016 to 2022. She was responsible forSutter Health'sintegrated network of 14,000 clinicians, 24 hospitals, outpatient services, research facilities, and home health and hospice care. Under her leadership,Ms. Krevansadvanced clinical programs, innovation, and digital health to make healthcare more accessible for patients.

    "Sarah is a highly accomplished healthcare leader with extensive experience in a dynamic and diverse environment," saidBob Ragusa, CEO of GRAIL. "I am confident that her experience will bring immense value to GRAIL as we move toward establishing a new standard of care for multi-cancer early detection for patients."

    Previously,Ms. Krevansserved as chief operating officer, and regional executive officer and president of theSutter Health Sacramento Sierra Region. She also held executive roles atKaiser Permanenteand served as deputy director ofMaine'sBureau of Medical Servicesand acting director of Medicaid, health planning and licensure programs.Ms. Krevans'experience as a board member includes serving on many not-for-profit boards and as Chair of theCalifornia Association of Hospitals. She currently serves on the board of theAcacium Groupand is the incoming Chair of CaringBridge.

    Ms. Krevansearned master's degrees in business administration and in public health from theUniversity of California,Berkeley, and a bachelor's degree fromBoston University. She has been named as one of the "Top 25 Women Leaders" byModern Healthcareand included onModern Healthcare'slist of the "100 Most Influential People in Healthcare."

    About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered inMenlo Park, CAwith locations inWashington, D.C.,North Carolina, and theUnited Kingdom.

    For more information, visitgrail.com.

    GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)

    CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/grail-appoints-sarah-krevans-to-board-of-directors-302282199.html

    SOURCEGRAIL, Inc.

    GRAIL Contacts, Corporate Communications, Kristen Davis, Trish Rowland, pr@grail.com; Investor Relations, Alex Dobbin, Alexis Tosti, ir@grail.com

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com